Alvogen has entered into exclusive commercial agreements in Canada, Israel and South Korea for the PF708 teriparatide candidate developed by its partner Pfenex. The Icelandic company has struck deals for the rival to Eli Lilly’s Forteo osteoporosis drug with JAMP Pharma in Canada, with Kamada in Israel and with Pharmbio Korea Inc. in Korea.
Tamer Group’s SAJA, Alvogen’s marketing partner for PF708 in the Middle East and Africa, has submitted a marketing authorization application...